Leukemia, B-Cell Clinical Trial
Official title:
Safety and Clinical Activity of CD19 Chimeric Antigen Receptor T Cells in Treating Patients With Recurrent or Refractory CD19 Positive B Cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic leukemia,and dynamically observe the changes of CAR-T in patients and the residual tumor.
In this single-center, open-label, single-arm, prospective clinical trial, a total of 20 recurrent or refractory CD19+ B cell acute lymphoblastic leukemia patients will be enrolled.After recruiting eligible patients,autologous peripheral blood mononuclear cells(PBMCs) will be purified from whole blood.The CD3+ T cells were subsequently selected and re-stimulated by anti-CD3 and anti-CD28 monoclonal antibodies.T cells will be transduced with lentiviral vector for the generation of the CD19 CART cell and administered by i.v. injection.The purpose of current study is to determine the safety and clinical efficacy of CD19 CAR T cells therapy in patients with recurrent or refractory CD19+ ALL. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03605589 -
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Recruiting |
NCT04649983 -
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03614858 -
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
|
Phase 1/Phase 2 | |
| Terminated |
NCT02848911 -
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
|
Phase 1 | |
| Terminated |
NCT02518750 -
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
|
Phase 2 | |
| Enrolling by invitation |
NCT03229200 -
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
|
Phase 4 | |
| Recruiting |
NCT04439721 -
γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse
|
Early Phase 1 | |
| Recruiting |
NCT02813837 -
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
|
N/A | |
| Recruiting |
NCT04271410 -
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03598179 -
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
|
Phase 2 | |
| Recruiting |
NCT05254743 -
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
| Recruiting |
NCT05010564 -
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
|
Phase 1 | |
| Recruiting |
NCT03564977 -
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT05362773 -
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT02672501 -
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06209671 -
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT03564470 -
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04271800 -
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01087294 -
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 1 |